미세잔존질환(MRD) 역학 시장 : 전략적 인사이트와 예측(2026-2031년)

The Minimal Residual Disease prevelance is projected to grow at a CAGR of 6.2% over the forecast period, increasing from USD 2.97 billion in 2026 to USD 4.02 billion by 2031.

The global Minimal Residual Disease (MRD) epidemiology market is gaining significant importance as advances in precision oncology and molecular diagnostics transform cancer management. MRD refers to the small number of cancer cells that remain in a patient's body after treatment and are often undetectable using conventional diagnostic methods. Epidemiological analysis of MRD focuses on understanding disease prevalence, incidence, diagnosed patient populations, treatment patterns, relapse rates, and long-term clinical outcomes across hematological malignancies and selected solid tumors. Growing adoption of MRD as a prognostic and predictive biomarker is driving demand for comprehensive epidemiological data to support clinical research, healthcare planning, pharmaceutical development, and commercialization strategies.

The increasing global burden of leukemia, lymphoma, multiple myeloma, and other hematologic cancers continues to expand the need for accurate MRD epidemiological studies. Pharmaceutical companies, diagnostic developers, healthcare providers, and regulatory agencies are increasingly utilizing patient population analyses to guide clinical trial design, evaluate treatment outcomes, identify unmet medical needs, and forecast future demand for MRD testing and targeted therapies. The growing integration of next-generation sequencing (NGS), polymerase chain reaction (PCR), flow cytometry, and liquid biopsy technologies is further enhancing disease monitoring and epidemiological research.

Growing investments in precision medicine, personalized oncology, and biomarker-driven treatment approaches are accelerating the development of comprehensive MRD epidemiology databases across major healthcare markets. Improvements in cancer registries, electronic health records, real-world evidence platforms, and AI-powered data analytics are expected to significantly improve the quality and accuracy of epidemiological forecasting throughout the forecast period.

Market Drivers

Rising Incidence of Hematological Malignancies

The increasing prevalence of leukemia, lymphoma, multiple myeloma, and other blood cancers is driving demand for detailed MRD epidemiology studies to support disease monitoring and treatment planning.

Growing patient populations continue expanding the need for epidemiological analysis.

Increasing Adoption of Precision Medicine

Personalized treatment strategies increasingly rely on MRD assessment for therapy selection, relapse prediction, and long-term disease management.

The shift toward biomarker-driven oncology continues supporting epidemiological research.

Advances in Molecular Diagnostics

Technologies including NGS, PCR, flow cytometry, and liquid biopsy are improving the sensitivity of MRD detection and enabling more accurate patient population assessment.

Technological innovation continues strengthening epidemiological data quality.

Growing Clinical Trial Activity

MRD endpoints are increasingly incorporated into oncology clinical trials to evaluate treatment efficacy and accelerate drug development.

The expansion of biomarker-based clinical research is increasing demand for epidemiological datasets.

Expansion of Real-World Evidence

Healthcare organizations are increasingly utilizing patient registries, electronic medical records, and real-world evidence to improve disease surveillance and epidemiological forecasting.

Advanced analytics continue enhancing healthcare decision-making.

Market Restraints

Limited Standardization of MRD Assessment

Differences in diagnostic methodologies, reporting standards, and clinical practice may affect the consistency of epidemiological data across healthcare systems.

Global harmonization efforts remain ongoing.

High Cost of Advanced Diagnostics

Sophisticated molecular testing platforms require significant investment, limiting widespread access in certain healthcare settings.

Testing accessibility continues to vary across regions.

Limited Data Availability in Emerging Markets

Incomplete cancer registries and variable healthcare reporting systems may reduce the availability of high-quality epidemiological information in developing countries.

Improved healthcare infrastructure is expected to address these limitations over time.

Technology and Segment Insights

By Disease Type

Acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), multiple myeloma, and lymphoma represent the largest segments for MRD epidemiological analysis due to their high reliance on residual disease monitoring.

MRD research is also expanding into selected solid tumors as diagnostic technologies continue to evolve.

By Diagnostic Technology

Next-generation sequencing and PCR-based assays account for a significant share of MRD assessment owing to their high sensitivity and accuracy.

Flow cytometry remains widely utilized for routine clinical monitoring, while liquid biopsy technologies are emerging as promising non-invasive alternatives.

By End User

Pharmaceutical and biotechnology companies represent major users of MRD epidemiology studies for drug development and market forecasting.

Research organizations, hospitals, diagnostic laboratories, academic institutions, and healthcare policymakers also rely extensively on epidemiological data for clinical decision-making and healthcare planning.

Regional Insights

North America represents the largest market for MRD epidemiology analysis due to its advanced healthcare infrastructure, high adoption of precision medicine, extensive cancer registries, and strong clinical research ecosystem. The United States continues to account for the largest diagnosed patient population and the highest level of MRD-related clinical activity.

Europe remains a major market, supported by well-established cancer research networks, expanding molecular diagnostics adoption, and increasing collaboration between healthcare providers and pharmaceutical companies.

Asia Pacific is expected to witness the fastest growth during the forecast period as healthcare infrastructure improves, cancer incidence increases, and investments in precision oncology and molecular diagnostics continue expanding across China, Japan, India, South Korea, and other countries.

Latin America and the Middle East & Africa are gradually strengthening their oncology research capabilities, improving disease surveillance systems, and expanding access to advanced diagnostic technologies.

Competitive and Strategic Outlook

The MRD epidemiology market is supported by collaborations among pharmaceutical companies, diagnostic developers, contract research organizations, academic institutions, healthcare providers, and data analytics companies. Organizations continue investing in real-world evidence generation, AI-powered epidemiological modeling, biomarker research, and integrated patient databases to improve disease forecasting and clinical decision-making.

Strategic initiatives include expanding cancer registries, integrating genomic data with clinical outcomes, developing standardized MRD reporting frameworks, strengthening international research collaborations, and supporting precision medicine initiatives. Increasing adoption of digital health technologies and advanced analytics is expected to further enhance epidemiological insights and improve patient stratification.

Conclusion

The global Minimal Residual Disease epidemiology market is expected to witness sustained growth throughout the forecast period, supported by increasing cancer incidence, expanding adoption of precision oncology, advances in molecular diagnostics, and growing reliance on biomarker-driven treatment strategies. Continuous improvements in real-world evidence generation, genomic technologies, AI-enabled analytics, and healthcare data integration are expected to create significant opportunities for epidemiological research and clinical development. Although challenges related to data standardization, diagnostic accessibility, and regional data availability remain, the expanding role of MRD in personalized cancer management will continue driving demand for comprehensive epidemiological analysis.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of global MRD epidemiology, patient populations, and disease trends.
• Competitive Landscape: Assessment of developments in diagnostics, clinical research, and epidemiology-driven drug development.
• Market Drivers and Future Trends: Analysis of precision medicine, molecular diagnostics, biomarker adoption, and real-world evidence.
• Actionable Recommendations: Support clinical development, commercial planning, investment decisions, and healthcare strategy.
• Caters to a Wide Audience: Valuable for pharmaceutical companies, biotechnology firms, diagnostic developers, healthcare providers, research organizations, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Patient population forecasting, epidemiological assessment, clinical trial planning, competitive intelligence, commercialization strategy, investment planning, market opportunity evaluation, healthcare resource planning, and strategic decision-making.

Report Coverage

• Historical analysis from 2021 to 2024, base year 2025, and forecast period from 2026 to 2031.
• Epidemiology analysis by disease indication, patient population, age group, gender, diagnostic technology, and geography.
• Assessment of disease prevalence, incidence, diagnosed cases, treatment patterns, relapse rates, mortality trends, and future patient forecasts.
• Analysis of market drivers, restraints, opportunities, clinical research developments, diagnostic innovations, and emerging epidemiological trends.
• Regional analysis covering North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Epidemiology Snapshot of Minimal Residual Disease (MRD)
• 1.2 Key Insights Across Hematologic Malignancies
• 1.3 MRD Testing Adoption Trends
• 1.4 Key Clinical and Diagnostic Insights
• 1.5 Analyst Perspective

2. Disease & Epidemiology Analysis

• 2.1 Overview of Minimal Residual Disease (MRD)
  • 2.1.1 Definition and Clinical Significance
  • 2.1.2 Role of MRD in Disease Monitoring
• 2.2 MRD in Hematologic Malignancies
  • 2.2.1 Acute Lymphoblastic Leukemia (ALL)
  • 2.2.2 Acute Myeloid Leukemia (AML)
  • 2.2.3 Chronic Lymphocytic Leukemia (CLL)
  • 2.2.4 Multiple Myeloma
  • 2.2.5 Non-Hodgkin Lymphoma (NHL)
  • 2.2.6 Other Hematologic Disorders
• 2.3 Global Incidence and Prevalence (Disease-Specific MRD Context)
  • 2.3.1 Incidence by Indication
  • 2.3.2 Prevalence by Indication
  • 2.3.3 Relapse Rates Associated with MRD Positivity
• 2.4 Patient Stratification and Risk Categorization
  • 2.4.1 MRD Positive vs MRD Negative Outcomes
  • 2.4.2 Prognostic Value of MRD
• 2.5 MRD Testing Penetration and Adoption Rates
• 2.6 Clinical Trial vs Real-World MRD Data Variability

3. Minimal Residual Disease Epidemiology Report Dynamics

• 3.1 Market Drivers
  • 3.1.1 Increasing Use of MRD as a Prognostic Biomarker
  • 3.1.2 Growing Adoption of Precision Oncology
  • 3.1.3 Expansion of Advanced Molecular Diagnostic Techniques
• 3.2 Market Restraints
  • 3.2.1 Limited Standardization Across MRD Testing Methods
  • 3.2.2 High Cost of Advanced MRD Diagnostics
  • 3.2.3 Variability in Clinical Interpretation
• 3.3 Market Opportunities
  • 3.3.1 Integration of MRD in Clinical Trial Endpoints
  • 3.3.2 Expansion in Solid Tumor MRD Applications
  • 3.3.3 Development of High-Sensitivity Diagnostic Platforms
• 3.4 Market Challenges
  • 3.4.1 Regulatory Alignment Across Regions
  • 3.4.2 Data Interpretation Complexity

4. Commercial & Market Access

• 4.1 Role of MRD in Treatment Decision-Making
• 4.2 MRD as a Surrogate Endpoint in Drug Approval
• 4.3 Reimbursement Landscape for MRD Testing
• 4.4 Adoption Across Academic vs Community Settings
• 4.5 Integration in Clinical Guidelines

5. Innovation & Pipeline Landscape

• 5.1 Overview of MRD Diagnostic Technologies
  • 5.1.1 Flow Cytometry-Based MRD Detection
  • 5.1.2 Polymerase Chain Reaction (PCR)-Based MRD
  • 5.1.3 Next-Generation Sequencing (NGS)-Based MRD
• 5.2 Pipeline Diagnostics (Verified Platforms)
  • 5.2.1 Adaptive Biotechnologies
    • 5.2.1.1 clonoSEQ (NGS-based MRD assay - FDA authorized)
    • 5.2.1.2 Indications: Multiple Myeloma, ALL, CLL
    • 5.2.1.3 Pipeline Expansion Studies (Clinical Trials)
  • 5.2.2 Guardant Health
    • 5.2.2.1 Guardant Reveal (liquid biopsy MRD test)
    • 5.2.2.2 Indications: Colorectal Cancer (MRD detection)
    • 5.2.2.3 Ongoing Clinical Validation
  • 5.2.3 Natera
    • 5.2.3.1 Signatera (personalized ctDNA MRD test)
    • 5.2.3.2 Indications: Multiple solid tumors
    • 5.2.3.3 Clinical Trial Evidence
• 5.3 Mechanism of Detection
  • 5.3.1 DNA-based Detection
  • 5.3.2 Immunophenotyping
  • 5.3.3 Circulating Tumor DNA (ctDNA)
• 5.4 Modality Trends
  • 5.4.1 Tissue-Based MRD
  • 5.4.2 Liquid Biopsy MRD

6. Treatment Landscape

• 6.1 Role of MRD in Therapy Optimization
• 6.2 MRD-Guided Treatment Strategies
• 6.3 Approved Therapies with MRD Relevance
  • 6.3.1 Bristol Myers Squibb
    • 6.3.1.1 Blinatumomab (Blincyto) - MRD-positive ALL
  • 6.3.2 AbbVie
    • 6.3.2.1 Venetoclax (Venclexta) - MRD-driven therapy in CLL
  • 6.3.3 Janssen Pharmaceuticals
    • 6.3.3.1 Daratumumab (Darzalex) - MRD endpoints in Multiple Myeloma
• 6.4 MRD in Treatment Response Monitoring
• 6.5 MRD in Relapse Prediction

7. Minimal Residual Disease Epidemiology Market Size & Forecast

• 7.1 Epidemiology-Linked Market Estimation (Historical)
• 7.2 Forecast Based on MRD Testing Adoption
• 7.3 Growth Drivers Linked to Diagnostic Penetration
• 7.4 Scenario-Based Forecasting

8. Minimal Residual Disease Epidemiology Report Segmentation

• 8.1 By Technology
  • 8.1.1 Flow Cytometry
  • 8.1.2 PCR-Based Assays
  • 8.1.3 Next-Generation Sequencing
• 8.2 By Indication
  • 8.2.1 Acute Lymphoblastic Leukemia
  • 8.2.2 Acute Myeloid Leukemia
  • 8.2.3 Chronic Lymphocytic Leukemia
  • 8.2.4 Multiple Myeloma
  • 8.2.5 Lymphomas
• 8.3 By Sample Type
  • 8.3.1 Bone Marrow
  • 8.3.2 Peripheral Blood
• 8.4 By End User
  • 8.4.1 Hospitals
  • 8.4.2 Diagnostic Laboratories
  • 8.4.3 Academic Research Centers

9. Geographical Analysis (Regional Level)

• 9.1 North America
• 9.2 Europe
• 9.3 Asia-Pacific
• 9.4 Latin America
• 9.5 Middle East & Africa

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 United States - FDA (MRD Biomarker Qualification & Diagnostics Approval)
• 11.2 Europe - EMA & IVDR Framework
• 11.3 Japan - PMDA Guidelines for Molecular Diagnostics
• 11.4 India - CDSCO Regulatory Landscape for In Vitro Diagnostics
• 11.5 China - NMPA Framework
• 11.6 Global Guidelines on MRD Usage
• 11.7 Clinical Practice Guidelines (e.g., NCCN, ESMO)
• 11.8 Data Standardization and Validation

12. Competitive Landscape

• 12.1 Market Share of MRD Diagnostic Providers
• 12.2 Technology Differentiation (NGS vs PCR vs Flow Cytometry)
• 12.3 Strategic Collaborations (Diagnostics + Pharma)
• 12.4 Mergers and Acquisitions
• 12.5 Investment Trends

13. Company Profiles

• 13.1 Adaptive Biotechnologies
  • 13.1.1 Approved Product: clonoSEQ (NGS MRD assay)
  • 13.1.2 Indications: Multiple Myeloma, ALL, CLL
  • 13.1.3 Pipeline Studies and Expansion
• 13.2 Natera
  • 13.2.1 Product: Signatera
  • 13.2.2 Indications: Solid tumors
  • 13.2.3 Clinical Validation
• 13.3 Guardant Health
  • 13.3.1 Product: Guardant Reveal
  • 13.3.2 Indications: Colorectal cancer
  • 13.3.3 Pipeline Studies
• 13.4 Invivoscribe
  • 13.4.1 MRD Testing Solutions
  • 13.4.2 Indications: Hematologic malignancies
• 13.5 F. Hoffmann-La Roche Ltd
  • 13.5.1 Diagnostic Division (Roche Diagnostics)
  • 13.5.2 Oncology Portfolio with MRD endpoints
• 13.6 Illumina
  • 13.6.1 Sequencing Platforms
  • 13.6.2 Role in MRD Detection
• 13.7 Thermo Fisher Scientific
  • 13.7.1 PCR & Sequencing Platforms
  • 13.7.2 MRD Applications
• 13.8 Qiagen
  • 13.8.1 Molecular Diagnostics Portfolio
  • 13.8.2 MRD Testing Support

14. Future Outlook

• 14.1 Expansion of MRD in Solid Tumors
• 14.2 Increasing Role as Regulatory Endpoint
• 14.3 Integration with AI and Digital Diagnostics
• 14.4 Long-Term Impact on Oncology Treatment Paradigms

15. Methodology

• 15.1 Research Design
• 15.2 Data Collection (Clinical Trials, Registries, Publications)
• 15.3 Epidemiology Modeling Approach
• 15.4 Validation Framework
• 15.5 Assumptions and Limitations